encompass health corp. - EHC
EHC
Close Chg Chg %
118.64 0.43 0.36%
Open Market
119.07
+0.43 (0.36%)
Volume: 326.68K
Last Updated:
Aug 13, 2025, 2:53 PM EDT
Company Overview: encompass health corp. - EHC
EHC Key Data
| Open $119.03 | Day Range 118.50 - 119.61 |
| 52 Week Range 85.92 - 123.13 | Market Cap $11.95B |
| Shares Outstanding 100.72M | Public Float 99.21M |
| Beta 0.88 | Rev. Per Employee N/A |
| P/E Ratio 23.19 | EPS $5.19 |
| Yield 57.32% | Dividend $0.19 |
| EX-DIVIDEND DATE Oct 1, 2025 | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.14M |
EHC Performance
| 1 Week | 0.89% | ||
| 1 Month | 0.17% | ||
| 3 Months | -1.85% | ||
| 1 Year | 33.86% | ||
| 5 Years | 133.64% |
EHC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
12
Full Ratings ➔
About encompass health corp. - EHC
Encompass Health Corp. engages in the provision of post-acute healthcare services. It provides specialized rehabilitative treatment on an inpatient basis. The company was founded by Richard M. Scrushy on February 22, 1984 and is headquartered in Birmingham, AL.
EHC At a Glance
Encompass Health Corp.
9001 Liberty Parkway
Birmingham, Alabama 35242
| Phone | 1-205-967-7116 | Revenue | 5.37B | |
| Industry | Medical/Nursing Services | Net Income | 452.90M | |
| Sector | Health Services | 2024 Sales Growth | 11.914% | |
| Fiscal Year-end | 12 / 2025 | Employees | 40,000 | |
| View SEC Filings |
EHC Valuation
| P/E Current | 23.195 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 20.711 |
| Price to Sales Ratio | 1.757 |
| Price to Book Ratio | 4.502 |
| Price to Cash Flow Ratio | 9.412 |
| Enterprise Value to EBITDA | 10.972 |
| Enterprise Value to Sales | 2.377 |
| Total Debt to Enterprise Value | 0.212 |
EHC Efficiency
| Revenue/Employee | 134,330.00 |
| Income Per Employee | 11,322.50 |
| Receivables Turnover | 8.973 |
| Total Asset Turnover | 0.85 |
EHC Liquidity
| Current Ratio | 1.055 |
| Quick Ratio | 1.055 |
| Cash Ratio | 0.193 |
EHC Profitability
| Gross Margin | 19.983 |
| Operating Margin | 16.089 |
| Pretax Margin | 13.951 |
| Net Margin | 8.429 |
| Return on Assets | 7.212 |
| Return on Equity | 24.536 |
| Return on Total Capital | 9.532 |
| Return on Invested Capital | 9.964 |
EHC Capital Structure
| Total Debt to Total Equity | 131.292 |
| Total Debt to Total Capital | 56.765 |
| Total Debt to Total Assets | 41.529 |
| Long-Term Debt to Equity | 123.314 |
| Long-Term Debt to Total Capital | 53.315 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Encompass Health Corp. - EHC
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 5.12B | 4.35B | 4.80B | 5.37B | |
Sales Growth
| +10.27% | -15.09% | +10.41% | +11.91% | |
Cost of Goods Sold (COGS) incl D&A
| 4.12B | 3.56B | 3.87B | 4.30B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 256.60M | 243.60M | 273.90M | 299.60M | |
Depreciation
| 200.20M | 214.80M | 241.40M | 270.80M | |
Amortization of Intangibles
| 56.40M | 28.80M | 32.50M | 28.80M | |
COGS Growth
| +7.20% | -13.45% | +8.52% | +11.16% | |
Gross Income
| 1.00B | 784.50M | 933.50M | 1.07B | |
Gross Income Growth
| +24.96% | -21.85% | +18.99% | +15.02% | |
Gross Profit Margin
| +19.60% | +18.04% | +19.44% | +19.98% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 197.30M | 154.30M | 201.70M | 209.20M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 197.30M | 154.30M | 201.70M | 209.20M | |
SGA Growth
| +26.88% | -21.79% | +30.72% | +3.72% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (2.80M) | 8.80M | 600.00K | |
EBIT after Unusual Expense
| 809.30M | 621.40M | 731.80M | 863.90M | |
Non Operating Income/Expense
| 12.50M | 5.10M | 18.90M | 23.10M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| 4.00M | 2.90M | 3.20M | 3.00M | |
Interest Expense
| 164.60M | 175.70M | 143.50M | 137.40M | |
Interest Expense Growth
| -10.64% | +6.74% | -18.33% | -4.25% | |
Gross Interest Expense
| 173.50M | 186.20M | 157.00M | 152.60M | |
Interest Capitalized
| 8.90M | 10.50M | 13.50M | 15.20M | |
Pretax Income
| 657.20M | 450.80M | 607.20M | 749.60M | |
Pretax Income Growth
| +39.06% | -31.41% | +34.69% | +23.45% | |
Pretax Margin
| +12.83% | +10.37% | +12.65% | +13.95% | |
Income Tax
| 139.60M | 100.10M | 132.20M | 150.20M | |
Income Tax - Current - Domestic
| 111.80M | 72.20M | 128.30M | 139.50M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 27.80M | 27.90M | 3.90M | 10.70M | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| 4.00M | 2.90M | 3.20M | 3.00M | |
Other After Tax Income (Expense)
| (1.80M) | (1.10M) | (2.40M) | (2.80M) | |
Consolidated Net Income
| 515.80M | 349.60M | 472.60M | 596.60M | |
Minority Interest Expense
| 105.00M | 93.60M | 111.00M | 140.90M | |
Net Income
| 410.80M | 256.00M | 361.60M | 455.70M | |
Net Income Growth
| +45.06% | -37.68% | +41.25% | +26.02% | |
Net Margin Growth
| +8.02% | +5.89% | +7.53% | +8.48% | |
Extraordinaries & Discontinued Operations
| (400.00K) | 13.80M | (12.00M) | (2.80M) | |
Discontinued Operations
| (400.00K) | 13.80M | (12.00M) | (2.80M) | |
Net Income After Extraordinaries
| 410.40M | 269.80M | 349.60M | 452.90M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 410.40M | 269.80M | 349.60M | 452.90M | |
EPS (Basic)
| 4.1454 | 2.7198 | 3.5136 | 4.5335 | |
EPS (Basic) Growth
| +44.33% | -34.39% | +29.19% | +29.03% | |
Basic Shares Outstanding
| 99.00M | 99.20M | 99.50M | 99.90M | |
EPS (Diluted)
| 4.1138 | 2.6992 | 3.4748 | 4.4589 | |
EPS (Diluted) Growth
| +44.46% | -34.39% | +28.73% | +28.32% | |
Diluted Shares Outstanding
| 100.20M | 100.40M | 101.30M | 102.20M | |
EBITDA
| 1.06B | 873.80M | 1.01B | 1.16B | |
EBITDA Growth
| +19.34% | -17.81% | +15.09% | +15.75% | |
EBITDA Margin
| +20.76% | +20.09% | +20.95% | +21.66% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 135.909 | |
| Number of Ratings | 12 | Current Quarters Estimate | 1.196 | |
| FY Report Date | 09 / 2025 | Current Year's Estimate | 5.275 | |
| Last Quarter’s Earnings | 1.40 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 4.43 | Next Fiscal Year Estimate | 5.798 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 12 | 12 | 12 | 12 |
| Mean Estimate | 1.20 | 1.30 | 5.27 | 5.80 |
| High Estimates | 1.27 | 1.35 | 5.32 | 6.20 |
| Low Estimate | 1.15 | 1.24 | 5.24 | 5.55 |
| Coefficient of Variance | 2.72 | 2.12 | 0.49 | 3.10 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 11 | 12 | 11 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 0 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Encompass Health Corp. - EHC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Encompass Health Corp. - EHC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 17, 2025 | Christopher R. Reidy Director | 14,781 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $106.89 per share | 1,579,941.09 |
| Jul 17, 2025 | Christopher R. Reidy Director | 14,448 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 17, 2025 | Kevin J. O'Connor Director | 9,881 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 17, 2025 | Nancy M. Schlichting Director | 21,186 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2025 | Mark J. Tarr President & CEO; Director | 583,376 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $35.06 per share | 20,453,162.56 |
| May 21, 2025 | Mark J. Tarr President & CEO; Director | 645,454 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $44.67 per share | 28,832,430.18 |
| May 21, 2025 | Mark J. Tarr President & CEO; Director | 645,360 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $120.94 per share | 78,049,838.40 |
| May 21, 2025 | Mark J. Tarr President & CEO; Director | 527,070 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $121.53 per share | 64,054,817.10 |
| May 21, 2025 | Mark J. Tarr President & CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Mark J. Tarr President & CEO; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 8, 2025 | Elissa Joy Charbonneau Chief Medical Officer | 11,958 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $116.61 per share | 1,394,422.38 |
| Mar 6, 2025 | Douglas E. Coltharp EVP & Chief Financial Officer | 12,407 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | John Patrick Darby EVP, Gen Counsel & Secretary | 6,032 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2025 | Andrew L. Price Chief Accounting Officer | 69,587 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $100.14 per share | 6,968,442.18 |
| Mar 4, 2025 | Edmund M. Fay Sr. Vice Pres. and Treasurer | 100,156 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $100.14 per share | 10,029,621.84 |
| Feb 27, 2025 | Andrew L. Price Chief Accounting Officer | 69,891 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $100.63 per share | 7,033,131.33 |
| Feb 27, 2025 | Douglas E. Coltharp EVP & Chief Financial Officer | 61,111 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $100.63 per share | 6,149,599.93 |
| Feb 27, 2025 | Edmund M. Fay Sr. Vice Pres. and Treasurer | 100,432 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $100.63 per share | 10,106,472.16 |
| Feb 27, 2025 | Elissa Joy Charbonneau Chief Medical Officer | 16,601 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $100.63 per share | 1,670,558.63 |
| Feb 27, 2025 | John Patrick Darby EVP, Gen Counsel & Secretary | 80,126 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $100.63 per share | 8,063,079.38 |